US › Healthcare

Grace Therapeutics, Inc. (GRCE)

US · Healthcare · Biotechnology

$2.13-0.47%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-15.8M

EPS

$-0.91

EPS estimate

$-0.18

EPS came in at -0.91 against a street estimate of -0.18 — a miss of 405.6%.

Key statistics

Market cap

$46.9M

Forward P/E

2.2

P/B

1.00

Book value

$2.96

EPS (TTM)

$-1.14

52-week high

$5.18

52-week low

$1.79

50-day MA

$2.24

200-day MA

$3.05

Beta

0.44

Analyst view

Analysts rate Grace Therapeutics, Inc. a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $5.99.

Shareholding

Insiders

18.68%

Institutions

31.51%

Largest institutional holders

Fund	Stake
HPM Partners LLC	4.04%
Eversept Partners, LP	3.67%
Nantahala Capital Management, LLC	3.46%
Bank of America Corp	2.35%
Vanguard Capital Management, LLC	1.91%
Citadel Advisors Llc	1.66%
Renaissance Technologies Corp	1.16%
Jane Street Group LLC	0.79%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Grace Therapeutics, Inc. — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.